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Cellular kinetics in rectal cancer
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Summary Measurements of dynamic tumour cell kinetic parameters, particularly the potential doubling time
(Tpo), may have potential as predictive assays for treatment outcome after radiotherapy. This paper details the
distributions of Tpot and other kinetic and DNA content parameters measured in rectal cancers. Biopsies were
taken from 119 patients approximately 6 h after infusion of 200mgm2 bromodeoxyuridine (BrdUrd). The
samples were analysed by bivariate DNA/BrdUrd flow cytometry. The primary purpose of the study was to
measure the kinetic parameters of labelling index (LI), duration of S-phase (Ts) and Tpo. Secondarily, tumour
DNA ploidy (DNA index) and S-phase fractions (SPFs) were also estimated from the univariate DNA
histograms. The 101 evaluable patients were classified according to clinical stage as T2 (n = 12), T3 (n = 53),
T4 (n = 28) or recurrent tumours (n = 8). Of the evaluable tumours, 73 were DNA aneuploid. The median LI,
Ts, and Tpo, of the aneuploid tumours were 21%, 20 h and 3.3 days respectively. The calculated LI, Ts, and
Tpot of diploid tumours were subject to uncertainties because of the contribution of normal cells. The LI and
SPF of all tumours were, however, significantly (P<0.001) correlated, having a correlation coefficient of only
0.76. The wide distributions of values for LI (quartiles 13.5%, 26.9%) and Tpot (quartiles 2.4, 5.6 days) that
were found are necessary baseline information if these parameters are to be useful in individual treatment
selection or as predictors of treatment outcome.
Keywords: rectal cancer; tumour cell kinetics; predictive assays; potential doubling time; bromodeoxyuridine
labelling index; flow cytometry
The curative treatment of rectal cancer presently consists in
surgical resection of the primary disease, often together with
pre- or post-operative pelvic radiotherapy, mostly combined
with chemotherapy. Adjuvant preoperative radiotherapy has
been shown to improve local control (Gerard et al., 1988);
chemotherapy combined with post-operative radiotherapy
improves disease-free and overall survival (Gastrointestinal
Tumor Study Group, 1985; Krook et al., 1991). Pathological
staging of the resected tumour has been shown to be the
single most important predictor of recurrence (Rich et al.,
1983). This knowledge, however, tells us little regarding the
mechanism of treatment failure. Better predictors of whether
the primary tumour will respond to radiotherapy and whether
additional or modified treatment is required would be help-
ful. There is currently considerable interest in the use of
pretreatment measurements of tumour dynamic kinetic para-
meters, for example tumour potential doubling time (Tpo), as
predictive assays for treatment response to radiotherapy (e.g.
Begg et al., 1992; Terry and Peters, 1993). Furthermore, it is
suggested that Tpo, may have value in selecting patients who
would benefit from accelerated radiotherapy (Begg et al.,
1992) or combined modality therapy (Rich et al., 1993). The
importance of accelerated repopulation of residual tumour
cells in rectal cancer has been inferred from the short interval
over which relapse occurs in patients treated with surgical
resection alone (Rich et al., 1993). A measurement of a
tumour's pretreatment growth potential might help assess an
individual's risk of pelvic relapse and whether combined-
modality therapy would be ultimately successful in achieving
local control, based on sterilisation of the primary tumour.
The principal purpose of the present study was to deter-
mine the distributions of kinetic parameters for rectal cancer.
The only comparable studies performed to date (Rew et al.,
1991; Wilson et al., 1993a,b) included tumours from both
colonic and rectal sites. Measurements were made of the
kinetic parameters Tp, labelling index (LI) and the duration
of S-phase (Ts). Tumour DNA ploidy and S-phase fractions
(SPFs) were measured concurrently. Many studies have been
performed to assess the predictive values of DNA ploidy and
SPF of rectal tumours measured by DNA flow cytometry
(Scott et al., 1987) and reviewed by Bauer (1993). While
measurements of these parameters may have prognostic
value, tumour ploidy per se does not suggest logical and
specific treatment modifications based on an acceptable
model for tumour response. In contrast, kinetic measure-
ments could be used to suggest a need for accelerated
treatments or for cell cycle-specific drugs. The patients
analysed in this study are being followed to determine treat-
ment outcome, and any correlations with these measured
parameters will be reported elsewhere.
Materials and methods
Patient population
After giving their informed consent, 119 patients with rectal
adenocarcinoma were perfused with 200 mg m2 bromode-
oxyuridine (BrdUrd) i.v. over a 20 min period. There was no
toxicity associated with this procedure. The 101 patients who
were evaluable (for at least one of the parameters of interest)
were classified according to clinical stage as T2, (n = 12), T3
(n = 53), T4 (n = 28) or recurrent tumours (n = 8) (American
Joint Committee on Cancer Staging, 1988).
Samplepreparation
At a known time (typically 6-8 h) thereafter, a biopsy sam-
ple or surgical specimen was taken, weighed, roughly chop-
ped with a scalpel and fixed in ice-cold 60% ethanol during
vigorous vortexing. Material was left in the fixative at refri-
gerator temperature for at least 15 h before proceeding.
Digestion and staining for incorporated BrdUrd and total
DNA content was essentially as we have described for
murine tumours (Carlton et al., 1991) with the important
difference being that the duration of pepsin digestion was
optimised, based on nuclei yield, for each individual speci-
men.
An attempt was made to use at least two different pepsin
digestion times for each specimen in order to reduce artifacts
due to incomplete digestion. Part of the fixed material was
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distributed between two 50 ml Ehrlenmeyer flasks each con-
taining 5 ml of 0.04% pepsin (EM Science, Cherry Hill, NJ,
USA) in 0.1 M hydrochloric acid at 37°C in a shaking water
bath. Aliquots were taken at 10 min intervals, and nuclei
were counted under a microscope with a haemocytometer.
The pepsin digestion was stopped when a high yield was
observed (typically 108 nuclei g-'). Two time points were
taken, usually 20 min apart, around this time of maximum
yield. Typical paired digestion times were 20 and 40 min, 40
and 60 min or 60 and 90 min. The use of two digestion
periods could routinely be accomplished in samples from
surgical specimens but was often not possible from biopsy
material because of the limited amounts ofmaterial available.
In these cases digestion in pepsin was stopped when the
nuclei yield was greater than 5 x I07 g-'.
The DNA denaturation and nuclei staining procedures
were the same for all samples and have been described in
detail elsewhere for cultured cells (Terry et al., 1991) and
murine tumours (Carlton et al., 1991). Following partial
denaturation of the DNA with 2 M hydrochloric acid, incor-
porated BrdUrd was visualised using a fluorescein isothio-
cyanate (FITC)-conjugated dual antibody procedure, and
total DNA content was determined with propidium iodide
(PI).
Flow cytometry
The flow cytometry in these studies was performed as we
have reported elsewhere (e.g. Carlton et al., 1991; Terry et
al., 1991). Briefly, bivariate distributions of BrdUrd content
(FITC) vs DNA content (PI) were measured using an EPICS
752 flow cytometer (Coulter, Hialeah, FL, USA) equipped
with narrow-beam (5ltm) excitation optics and a quartz flow
cell. Excitation was at 488 nm using a 5 W argon-ion laser
operating at 200 mW. BrdUrd was measured using a loga-
rithmic amplifier with a 530 nm short-pass filter, and DNA
content with a 610'nm long-pass filter. Most doublets and
clumps were excluded from the analysis by gating on a plot
of the red peak vs integral signal. In most cases 50 000 events
were collected in each final gated histogram. In some of the
smaller biopsy samples data from only 30 000 nuclei were
collected. A combination of Multicycle, Multi2d (Phoenix
Flow Systems, San Diego, CA, USA) and special-purpose
software that we have developed (White and Terry, 1992)
was used to analyse the data. The deconvolution of the DNA
histograms included subtraction of background and debris
but not of any aggregates as hardware gating was employed.
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All cases had less than 20% debris; most had less than 10%
debris.
Calculation ofkinetic parameters
Our analytical methodology is described in detail elsewhere
(Terry et al., 1992a,b) and is only briefly outlined here. A
quantity v was first calculated from the fractions of BrdUrd-
labelled nuclei obtained from the bivariate DNA vs. BrdUrd
histogram, where v = ln[(l +f`u(t))/(l -jfd(t)/2)], and fu(t)
andfJd(t) denote the fractions of labelled undivided cells and
labelled divided cells, respectively, at time t after labelling
(White et al., 1990). The relative movement of the BrdUrd-
labelled cells that remained undivided at the time of biopsy
between the GI and G2M tumour peaks (measured from the
univariate DNA histogram) was' used, together with v, to
compute the duration of S-phase, Ts (Terry et al., 1992a,b).
Tpot was then calculated from Tpo = ln(2)Ts/v. In circum-
stances where it was apparent that the time between BrdUrd
labelling and tumour sampling was less than the duration of
G2 and mitosis, the correction suggested by Ritter et al.
(1992) was used to calculate Ts. The tumour labelling index
(LI) is the calculated percentage of tumour cells that, at the
time of injection, was labelled by BrdUrd. The apparent LI
at the time of sampling must be corrected for cell division in
the time between BrdUrd labelling and biopsy. LI was cal-
culated directly from LI = e3v(ev- 1) (Carlton et al.,
1991).
Results
Sample preparation
Adequate sample preparation is important in this type of
study. Figure 1 shows an example in which a homogenate of
a single sample was digested in two different ways. Figure la
shows the bivariate DNA vs. BrdUrd histogram obtained
following a 90 min digestion of the specimen in pepsin yield-
ing approximately 108 nuclei per gram. A near-tetraploid
component of the tumour is clearly visible. In contrast,
Figure lb shows data from the same sample when digestion
was arbitrarily stopped at 60 min. Here the yield was only
5 x 106 nuclei per gram of tissue. In this case only a DNA
diploid population was observed; the small peaks to the right
of the G2 diploid peak represent some ungated clumps (as the
major component is at 6c, not 8c). It also follows that
measured values of LI, Ts, Tpo, and SPF would be quite
b
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Figure 1 The effect of different pepsin digestion times on the final flow cytometric histogram. (a) Ninety minutes in pepsin; a
near-tetraploid population is seen. (b) Sixty minutes in pepsin; only a diploid population is present. The presence of clumps is
indicated and the positions of diploid GI and G2 (GID, G2D) and aneuploid (GIA, G2A) peaks are shown on the DNA
projections of the bivariate DNA vs. BrdUrd histograms.
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nldifferent between the two digestions as two essentially
different populations would be measured. While it was not
possible to assess independently the proportions of tumour
and normal stroma in the small biopsy material that con-
stituted the bulk of the samples in this study, the tailoring of
individual sample preparations to maximise nuclei yield in-
creases the chance of obtaining a suspension that is represen-
tative of the cellular composition of the biopsy.
Of the 119 tumour samples obtained, 101 (85%) produced
analysable DNA histograms. Of the remainder, four samples
were wrongly fixed, in nine cases too few cells were produced
to run on the flow cytometer, two samples were incompletely
digested resulting in an artifactual smearing of the DNA vs.
BrdUrd histograms, and in three cases the DNA profiles
were uninterpretable owing to multiple overlapping similar
ploidy populations that were not distinguishable from each
other. The coefficients of variation of the DNA histograms
(measured on the DNA diploid GI peak) had a median value
of 3.2% with a range from 1.5% to 9.8%. It is noteworthy
that only two of the 101 cases produced histograms with
coefficients of variation (CV) greater than 6.5% and only 14
had CVs greater than 4.5%.
Labelling index
The LI of 89 of the tumours could be determined. (In the
remaining 12 cases the presence of overlapping labelled
populations owing to either tetraploidy, multiple aneuploidy
or an inappropriate time interval between labelling and
sampling made measurement of LI impossible.) The distribu-
tions for the diploid and aneuploid tumours are presented in
Figure 2. The mean LI of the aneuploid cells in the aneu-
ploid tumours was 22% (Tables I and II). Although this
appears to be significantly higher than that observed in dip-
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Figure 2 Distributions of labelling indices (LI) for diploid (a)
and aneuploid (b) tumours.
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loid tumours, it is not legitimate to compare the two. In
diploid tumours we cannot distinguish between normal and
tumour cells and hence the overall LI reflects an average of
the two populations.
In order to estimate LI for the normal cell populations-in
rectal tissue, we measured the LI of normal tissue taken from
surgical resections from five patients. The mean LI was 1.3%
(range 0.5-2.3%), a much lower value than that observed in
tumours. Only 2 of 27 diploid tumours had LIs of less than
2.3%, indicating that the biopsies do indeed contain more
proliferative tumour tissue. However, it should be noted that
the LI of samples from normal tissue obtained by biopsy
might be expected to be higher than those obtained by
surgery since the biopsies would be enriched for proliferating
epithelial cells in the mucosa, while the surgically removed
tissue may contain more of the non-proliferating submucosal
and muscularis cells.
The aneuploid (excluding recurrent) tumours appeared to
show a trend towards decreasing LI with increasing stage
(Table I). This trend, however, was not statistically
significant. The method of obtaining the sample had no
significant effect on the measured values of LI.
The volumes of the tumours from 62 of the patients were
measured from available computerised tomographic (CT)
scans. Volumes ranged from 2.7 to 365 cm3. More advanced
tumours tended to be larger than the earlier stage ones
(r = 0.30, P= 0.017, Spearman's rank correlation); there was,
however, extensive overlap between the different stages. For
example the median (and quartile) values were 26.5 (8.9-
53.5), 30.3 (16.3-42.4) and 55.6 (24.0-97.0)cm3 for T2, T3
and T4 tumours respectively. There was no correlation
between volume and LI either when all stages were grouped
or for samples within any of the individual stages (T2, T3 or
T4; data not shown).
Both LI and SPF are approximate measures of a popula-
tion's proliferative capability. Because of our interest in
obtaining Tpot we need to label with BrdUrd and measure LI
(or the related quantity v). We also calculated SPF values
from the univariate DNA histograms without knowledge of
the bivariate data and then compared the values of SPF and
LI in this group of tumours. The values of SPF and LI for
the total population were indeed related to each other as
expected. The Spearman (non-parametric) correlation
Table I Labelling indices and S-phase fractions by tumourploidy and
stage (mean ± s.e.m.)
Number Labelling S-phase
ofsamples index (%) fraction (%)
Diploida 27 12.0 1.6 11.8 1.4
Aneuploida 62 21.7 1.4 24.6 1.4
Aneuploidb
Stage T2 10 24.3 + 2.4 25.0 ± 2.4
Stage T3 30 22.6 2.0 23.8 1.9
Stage T4 17 17.0 2.5 22.9 ± 3.6
Recurrent 5 26.1 _ 6.2 33.6 ± 5.0
aLabelling indices cannot becompared because the labelling index of
aneuploid tumours is calculated from only the aneuploid cells
(presumed to betumour)and thatofdiploid tumours iscalculated from
allcells(normaldiploidandtumourdiploid).bValuesfordifferentstages
not significantly different by Kruskal-Wallis one-way analysis of
variance (non-parametric).
Table II Summary of kinetic parameters for aneuploid tumours
S-phasefraction Labelling index T, TpoI
(%) (%) (hrs) (days)
Number 62 62 60 60
Evaluable
Median 23.5 21.2 20.7 3.3
Range 0-57 1.9-58.7 6.7-62.6 1.2-20.5
Quartiles 17.0, 30.3 13.5, 26.9 14.6, 28.7 2.4, 5.6
Mean ± s.e.m. 21.6 ± 1.4 21.7 ± 1.4 22.3 ± 1.3 4.5 ± 0.4
aRectal cancerkinetics
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coefficient between the two was 0.76, which was highly
significant at P<0.001. This correlation coefficient of 0.76 is,
however, far from perfect, as can be seen from the scatter in
the plot of the two values against each other (Figure 3). The
correlation between SPF and LI was much better for the
diploid (r = 0.88) than for the aneuploid tumours (r = 0.62).
Hence, despite the relationship between the parameters
overall, the two measures may give very different values for
any individual patient. The regression line relating the two
parameters was SPF = (0.812 x LI) + 5.4% (all tumours).
Thus, at low values, the SPF gives a higher value of pro-
liferative index than does LI, probably because of the
presence of noise, debris, normal cells and aggregates in the
DNA histogram, despite the gating and debris subtraction
procedures used. The regression equation for the diploid
tumours, [SPF = (0.825 x LI) + 1.9%], had a much lower
intercept than that for the aneuploid tumours.
Tumourploidy
Of the 101 evaluable tumours, 28 were diploid, and the rest
were broadly, and bimodally, distributed with modes at
DNA indices of about 1.2 and 1.6 (Figure 4). Six of the
tumours displayed two aneuploid subpopulations; the DNA
index of the majority population was considered to be the
DNA index of the tumour.
In the present study, based on results from aneuploid
tumours, in which normal and tumour cells can be resolved,
we found that a median of 48% (range 10-95%; quartiles
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38-65%) of the cells in the suspensions prepared for flow
cytometry were aneuploid and hence definitively tumour
cells.
We analysed the dependence of the distribution of ploidies
on the method used to obtain the sample (Table III). There
was a significant increase in the incidence of diploid tumours
when samples were obtained by biopsy rather than surgically.
This was not a result of different tumour stages; even within
the T3 tumours alone, there was a significant difference in the
incidence of diploid tumours by method. To test for one
possible explanation for this difference, that a sigmoidoscope-
guided biopsy could miss the tumour site, we have recently
been obtaining biopsies during endoscopic ultrasound
examination. The results show no evidence for a different
incidence of diploid tumours obtained by endoscopically
guided vs. sigmoidoscope-guided biopsy (Table III).
We next examined whether the incidence of aneuploidy
varied by stage of tumour. There was a stage dependency,
with T3 and recurrent tumours showing the lowest propor-
tion of aneuploidy both when all tumours or only the sam-
ples obtained by biopsy were considered (Table III). The
statistical significance of this finding is, however, marginal.
The aneuploid tumours were further divided into hypodi-
ploid, near diploid, near tetraploid and multiploid categories.
There were no significant differences among the tumours of
different stages relative to the different categories of aneu-
ploidy (data not shown).
Dynamic kinetic parameters (Ts, Tp,0)
The dynamic kinetic parameters were calculated from the
relative movement of labelled cells and other features of the
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Figure 3 Relationship between BrdUrd labelling index (LI;
measured from the bivariate DNA vs. BrdUrd histogram) and
S-phase fraction (SPF; estimated by modelled deconvolution of
the univariate DNA histogram) for 89 rectal adenocarcinomas.
Diploid (0) and aneuploid (V) tumours are distinguished. Solid
line, fit to all the data; upper dashed line, aneuploid tumours
only; lower dashed line, diploid tumours only.
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Figure 4 Distribution of DNA ploidy values for 73 aneuploid
rectal adenocarcinomas.
Table III Distribution of tumour ploidy by stage and sampling method
Aneuploid Diploid Significance of
n (%) (%) differencea
All samples 101 72 28
Surgery 15 100 0
Biopsy 86 67 33 P= 0.01
Biopsy (sigmoidoscopic) 62 71 29
Biopsy (ultrasound) 24 58 42 NS
Stage T2 II 100 0
Stage T3 52 63 37
Stage T4 30 80 20 P = 0.03 (T2,T3,T4 only)
Recurrent 8 62 38 P = 0.06 (all stages)
Biopsies only
Stage T2 7 100 0
Stage T3 43 56 44
Stage T4 29 79 21 P = 0.02 (T2,T3,T4 only)
Recurrent 7 57 43 P = 0.04 (all stages)
aCalculated using Pearson's chi-square.
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Figure 5 Distributions of the duration of S-phase (Ts, a) and the
potential doubling time (Tpo, b) of 60 evaluable aneuploid
tumours.
bivariate DNA histogram. The median duration of S-phase
of tumour cells in the 60 evaluable aneuploid tumours was
20.7 h (quartiles 14.6, 28.7 h). The distribution of these
values is presented as a histogram in Figure 5. For the
aneuploid tumours there was no difference in Ts values as a
function of tumour stage.
The median Ts for aneuploid tumours, 20.7 h, is higher
than that of 15.2 h obtained in the 28 diploid tumours
evaluated. The latter value is reflective of both the tumour
and normal cells in the sample. The median Ts of normal
tissue, based on four samples, was 16.3 h (range 12.4, 19.1 h),
which is indeed shorter than the Ts of tumour cells ascer-
tained from the aneuploid tumours.
The median Tpot for the 60 evaluable aneuploid tumours
was 3.3 days (quartiles 2.4, 5.6 days) (Table II). The distribu-
tion of these values is also presented as a histogram in Figure
5. There was no dependence of Tpot on tumour stage in this
study.
Some investigators attempt to calculate Tpot values from
diploid tumours (Rew et al., 1991). If we do so the value we
obtain is a median of 5.5 days. Of these 8/28 (29%) had Tpot
values shorter than 3.3 days, which was the median value for
aneuploid tumours.
Discussion
The distribution of ploidy values found in the present study
(Figure 4) does not differ qualitatively from that found by
others. Seventy-three (72%) of the cases were DNA aneu-
ploid. Several studies have shown an increased incidence of
aneuploidy with grade and stage of disease (Bauer, 1993), but
most of these studies included both colonic and rectal
cancers. In a study in which rectal cancers predominated
Giaretti and Santi (1990) reported a 75% incidence of aneu-
ploidy that was independent of tumour grade but had some
correlation with tumour size. In the present study there was a
dependence of aneuploidy on stage (Table III), however there
was no orderly progression of the incidence of aneuploidy
with increasing stage (T3 was the lowest). Hence, we cannot
Rectal cancerkinetics
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attach any biological significance to this finding. More data
need to be collected to determine whether or not the present
result is reproducible.
The important role of sample preparation in studies such
as these can best be seen in the significant decrease in the
incidence of aneuploid tumours when the data were obtained
from biopsies as compared with surgical specimens (Table
III). The possibility that it was due to missing the tumour
site could not be confirmed when sigmoidoscopic biopsies
were compared with material taken during endoscopic ultra-
sound examination. It is more likely that this reduced
incidence of aneuploidy is related to the difficulty of making
more than one preparation from small tumour biopsies. We
have previously shown for head and neck cancer specimens
that different pepsin digestion times can result in strikingly
different flow cytometric profiles despite the fact that they
may have been prepared from a homogenate of the same
specimen (Terry and Peters, 1993). Tumours that under
optimal digestion conditions would show the presence of an
aneuploid population might, if prepared inadequately, be
misclassified as diploid. In the surgical specimens contri-
buting to this study two (or more) different pepsin digestion
times were routinely employed from a homogenate of the
tissue sample. Since no pepsin digestion procedure can be
considered 'standard', even for tumours of similar histologies
from the same site, we suggest that the lowered incidence of
aneuploid tumours observed in biopsies is due to the reduced
possibility of making multiple preparations from very small
(<25 mg) samples.
The measurement of SPF, or the fraction of cells both in S
and G2M phases, by modelled deconvolution of DNA flow
cytometric histograms has long been used as a surrogate
measure of proliferative capacity. As recently reviewed
(Bauer, 1993; Bauer et al., 1993), the prognostic significance
of SPF measurements in rectal cancer is unclear. Part of this
difficulty has to do with the imprecisions involved in comput-
ing SPF from the histogram (Vindel0v and Christensen,
1990) owing to the presence of overlapping populations,
presence of debris (Haag et al., 1987), nature of the underly-
ing algorithm that is employed to model the data (Dean,
1985; Scott et al., 1992) and type of fluorochrome employed
(Dean et al., 1982). Furthermore, there is well-documented
evidence (Darzynkiewicz et al., 1980; Allison et al., 1983,
1985; White et al., 1994) for the presence of non-cycling cells
with S-phase DNA contents that will further confound the
relationship between SPF (even if measured perfectly) and
proliferative status. Despite these problems, some studies
have indeed shown relationships between proliferative
activity, as measured by SPF, and tumour response or treat-
ment outcome (Crissman et al., 1989; Bauer, 1993; Bauer et
al., 1993).
Many of these difficulties in estimating proliferative
activity can be obviated by measuring the fractions of DNA-
synthesising cells with an independent marker (FITC-con-
jugated antibodies to incorporated BrdUrd). The data in
Figure 3 show that, although there was a correlation between
SPF and LI in the present study, there was considerable
scatter in the data. For any given value of LI, values of SPF
varied with a coefficient of variation of about 40%. The best
fit regression did not pass through the origin but was offset
to a positive value for SPF at a zero value of LI. This was
probably due to the overestimation of SPF in samples with a
low proliferative fraction, in which case the confounding
problems detailed above would be most influential. Hence, it
is likely that a measure of LI will be of more utility for
estimating the proliferative capacity of cells within human
tumours than is measurement of SPF (Vindel0v and Chris-
tensen, 1990).
As mentioned above, it is not strictly possible to calculate
the LI of diploid tumours owing to the complete overlap of
the DNA profile of normal cells within the tumour. Like us,
other authors who have attempted to estimate the flow cyto-
metric LI of diploid tumours (Rew et al., 1991) report a
lower total LI for diploid tumours. This is in contrast to the
autoradiographic tritiated thymidine studies of Costa et al.
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(1992), in which no difference was observed between the
range of LI values found for both diploid and aneuploid
tumours. In aneuploid tumours we found that a median of
48% of the cells in the suspensions prepared for flow
cytometry were aneuploid, and hence definitely tumour cells.
We would expect the same percentages of normal and
tumour cells in diploid tumours. For instance if 48% of the
cells in tumours were tumour cells, the LI of these tumour
cells is 21.7% and the LI of normal tissue is 1.3%, we would
expect the LI of diploid tumours to be 11.1%. This is very
close to the mean value of 12.0% we obtained. Therefore, we
can attribute the lower LI of the diploid tumours to the
admixture of normal and tumour cells. Rew et al. (1991)
came to the same conclusion based on the total LI of aneu-
ploid vs. diploid tumours.
Among the aneuploid (excluding recurrent) tumours there
was a non-significant trend for decreasing LI with increasing
stage. There was also a trend for the later stage tumours to
be larger than the earlier stages. The smaller tumours tended
to have higher LI values, but this trend also did not reach
significance. Costa et al. (1992) found no correlation between
[3H]dT LI values and Dukes' stage. Rew et al. (1991) also
saw a trend towards a higher LI with increasing grade and
stage, but like ours the trend was not statistically significant.
The data of Costa et al. (1992) did suggest lower LI values
for colonic, as compared with rectal, tumours. Colonic and
rectal sites should be evaluated separately as also
recommended by the recent consensus review (Bauer et al.,
1993).
The wide range of values of LI (2% to > 50%) strengthens
the potential for in vivo measurement of LI to be a useful
candidate as a predictor of treatment response. There is a
striking numerical difference between the LI values reported
here and the only other similar study published to date (Rew
et al., 1991), where the authors report, for aneuploid
tumours, a range of LI values of 2-26% with a much lower
mean value of 12.1% (median 12.0%). [In a study of the
reliability and reproducibility of measurement of kinetic
parameters in colorectal cancer (Wilson et al., 1993a) the
same group reports mean values of LI of 14% and 16%
depending on where the analysis was performed.] Differences
in tumour sites appear to be the major contributor to the
interlaboratory differences in LI. The inclusion of colonic
and caecal cancers, with lower proliferative fractions, in the
data of Rew et al. (1991) and Wilson et al. (1993a), would
reduce the mean value of the population. Several methodo-
logical differences can also contribute to the difference. First-
ly, in the present study LI was calculated in terms of v and
takes into account the division of both labelled and
unlabelled cells in the time interval between BrdUrd adminis-
tration and tumour sampling. The other authors correct only
for the labelled cells that have divided, which would usually
result in a slightly low estimate of the true value of LI.
Modelling of the DNA profile to obtain the total number of
tumour cells, as used in the present study, will result in lower
numbers of cells in the total population than if the total is
estimated directly from the bivariate DNA vs. BrdUrd histo-
gram and also a higher LI. Furthermore, the present study
also used objective criteria (White and Terry, 1992) to distin-
guish BrdUrd-labelled from unlabelled cells in instances when
this distinction was not absolute.
The major advantage of the present methodology is that it
allows for estimation of the 'dynamic' kinetic parameters of
duration of S-phase, Ts, and the potential doubling time,
Tpot As shown in Figure 5, wide ranges of values of both
these quantities were found. Ts values ranged from 7 to 62 h
(mean 22.3 h, median 20.7 h) in the 60 evaluable aneuploid
tumours. For the 28 diploid tumours a shorter median Ts
value of 15.2 h was found. In the case of diploid tumours the
estimates included both tumour and normal cells within the
samples, and the median value was close to that of 16.3 h
found in normal rectal tissue. The estimates of Ts for aneu-
ploid tumours made in this study are approximately 40%
longer than those reported by Rew et al. (1991) and Wilson
et al. (1993a), who reported ranges of 5.5-28.6 h (mean 16.3,
median 15.0 h) and 4.6-59.1 h (mean 17.5 or 19.2 h depend-
ing on the analysing laboratory). Part of the reason for the
longer estimates of median Ts values found in the present
study results from the more rigorous analytical procedures
employed, which can be shown by modelling to give an
estimate of Ts approximately 20% longer than the simpler,
original approach (Begg et al., 1985) which was used by Rew
et al. (1991).
The derived values of Tpot for the aneuploid tumours
(Figure 5) ranged widely from 1 to 21 days (median 3.3
days). These values are similar to those reported by Rew et
al. (1991) for aneuploid tumours (range 1-15 days, median
3.5 days). This similarity in median values is, however,
largely fortuitous and results from the fact that Tpot is related
approximately to the ratio of LI and Ts. Hence the longer Ts
and higher LI values in the present study still resulted in a
similar median Tpot
Some investigators attempt to calculate Tpot values from
diploid tumours. If we do so the median is 5.5 days, but we
believe that Tpot cannot be properly calculated for diploid
tumours from data such as these because of the combination
of normal and tumour cells in the histograms. The admixture
of normal cells will on the average tend to reduce the LI and
shorten the Ts. Since Tpt is approximately proportional to
Ts/LI, these two factors tend to counterbalance each other.
The effect of normal tissue contamination on average LI is,
however, greater than its effect on Ts. The calculated Tpot for
the entire cell population, therefore, will in general be an
overestimate of the true Tpt of the tumour cells. It was noted
that 8/28 (29%) of diploid tumours had calculated Tpt values
shorter than 3.3 days, which was the median value for aneu-
ploid tumours. Since short Tpt values may indicate a require-
ment for accelerated fractionation radiotherapy, and Tpot(diploid)
will, usually, represent an upper limit of Tpot(tumor), this still
might be useful for selection of patients for accelerated frac-
tionation.
No attempt was made to investigate the influence of
tumour heterogeneity in this study. While heterogeneity, with
respect to the computed parameters, undoubtedly exists,
other authors (Wilson et al., 1993a,b) have demonstrated, in
colorectal cancer, that intra-tumour heterogeneity is a smaller
contributor to the total variance than are inter-patient
differences. We are firmly of the opinion that much of the
perceived heterogeneity within tumours can be ascribed to
sample preparative techniques. Others have suggested making
preparations from a homogenate of biopsies from several
sites (Wilson et al., 1993b). We are in agreement with this
general procedure, but suggest further that multiple prepara-
tions, each individually tailored to maximise nuclei yield, be
used to alleviate the problems of selective representation of
subpopulations of cells.
In conclusion, this paper details the distribution of kinetic
parameters that have potential utility as independent predic-
tors of treatment response and outcome. This baseline in-
formation is required if measurements of pretreatment
tumour kinetics are to play a role in the selection of
adjuvant, or extra, therapy on an individual patient basis.
The bivariate DNA vs. BrdUrd technique provides additional
information compared with flow-cytometric measures of
DNA alone. No evidence of toxicity was observed, and the
procedure is practical. Standardisation of sample preparation
and data analysis is still needed, and the various groups
involved in similar studies are working towards this end
(Wilson et al., 1993a,b; Terry et al., 1993). The present data,
showing wide ranges of values of LI and Tpot in rectal cancer,
suggest that these parameters could be of value both as
predictive assays of treatment outcome and for patient selec-
tion for altered treatment regimens. Furthermore, DNA dip-
loid and aneuploid tumours must be evaluated separately,
and the uncertainties in estimates of LI, Ts, and T.., in
diploid tumours should be appreciated.
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